"Global Top 20" Shows US and UK Have the Most Influential Experts in Breast Cancer Research

Share Article

Social Network Analysis of over 44,000 people by Lnx Pharma reveals key opinion leaders, power clusters and centers of excellence around the world in the research of breast neoplasms (breast cancer).

It’s fascinating to watch a network map unfold, particularly in such a large pool of researchers as breast cancer. You can literally see patterns emerge...

In the ongoing battle to fight breast cancer, thousands of physicians and research scientists dedicate their time and often their entire careers to finding a cure. Some of them attain fame; others prefer some level of anonymity outside their circle of research colleagues, but may still be considered a powerful authority. Lnx Pharma, a market research firm specializing in Key Opinion Leaders in the pharmaceutical industry, has released its Global Top 20 list of most influential people in the field of breast cancer research.

Nearly half the list resides in the United States (nine of the Top 20), with United Kingdom contributing four - possibly not surprising given the amount of research dollars raised by those countries. Nearly all (80%) have medical degrees, and most of the doctors on the list work in universities. Several are "rising stars," meaning they are early in their careers but have already earned significant respect by their peers and industry publications.

The Lnx Pharma Global Top 20 most influential researchers in breast cancer are:

  •     Gabriel Hortobágyi, MD - Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center (USA)
  •     Ian Ellis, MD, PhD - Molecular Medical Sciences, Department of Histopathology, University of Nottingham, Nottingham City Hospital NHS Trust (UK)
  •     Eric Winer, MD - Director, Breast Oncology Center; Chief, Division of Women's Cancers; Thompson Senior Investigator in Breast Cancer Research, Dana-Farber Cancer Institute (USA)
  •     Judy Garber, MD - Director, Cancer Risk and Prevention Program, Dana-Farber Cancer Institute (USA)
  •     Nadia Harbeck, MD, PhD - Head of The Breast Center, University of Cologne (Germany)
  •     Martine Piccart-Gebhart, MD, PhD - Associate Professor in Oncology, Universite Libre de Bruxelles (Belgium)
  •     Mitch Dowsett, PhD - Professor of Biochemical Endocrinology; Head of the Academic Department of Biochemistry and Head of Breast Cancer Translational Research, Royal Marsden Hospital and Institute of Cancer Research (UK)
  •     Jan Klijn, MD, PhD - Department of Medical Oncology, Rotterdam Cancer Institute (The Netherlands)
  •     Fergus Couch, PhD - Professor, Department of Laboratory Medicine and Pathology, Mayo Clinic (USA)
  •     Susan Domchek, MD - Abramson Cancer Centre, University of Pennsylvania School of Medicine (USA)
  •     Daniel Hayes, MD - Professor, Department of Internal Medicine, University of Michigan Health System (USA)
  •     James Ingle, MD - Head, Breast Cancer Research Program, Mayo Medical School (USA)
  •     Charles Perou, PhD - Associate Professor, UNC School of Medicine (USA)
  •     Aman Buzdar, MD - Professor of Medicine, The University of Texas MD Anderson Cancer Center (USA)
  •     Hironobu Sasano, MD, PhD - Department of Pathology, Tohoku University School of Medicine (Japan)
  •     Kathy Pritchard, MD - Sunnybrook Odette Cancer Centre, University of Toronto (Canada)
  •     Marc van de Vijver, MD, PhD - Divisions of Diagnostic Oncology, Netherlands Cancer Institute (The Netherlands)
  •     Douglas Easton, PhD - CR-UK Genetic Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge (UK)
  •     Rita Schmutzler, MD - Center of Familial Breast and Ovarian Cancer, University Hospital of Cologne (Germany)
  •     David Cameron, MD - Directorate of Oncology, University of Edinburgh & Western General Hospital (UK)

Methodology

There is much controversy over how to "score" the value of an expert or key opinion leader, particularly in medical research. Usually, a count of citations in literature and speaking engagements is used to gauge influence. Instead, Lnx Pharma applies a complex scoring methodology based in Social Network Analysis, a science which recognizes that those individuals who are most deeply or widely connected to a network have the greater likelihood of gaining acceptance for their ideas, and for innovating through exposure to new ideas.

Lnx Pharma analyzed over 20,000 articles published in the last three years related to breast neoplasms, the industry term for breast cancer, and cross referenced the literature with multiple data points to determine relationships. Over 44,000 people were analyzed in what is called the "giant component," or the core breast cancer community. After analysis of who these people were, who they were connected to, the value of those people and the strengths of those relationships, over 600 people emerged as an "invisible college" which is the term Lnx Pharma uses to describe a collection of individuals with strong ties to each other across multiple commonalities.

"It's fascinating to watch a network map unfold, particularly in such a large pool of researchers as breast cancer provides," said Philip Topham, General Manager of Lnx Pharma. "You can literally see patterns emerge around people and geographic regions, as well as specific segments within the field of study. What generally comes out at the end is not just a list of names, but actually a topographical map that can be used by pharmaceutical companies and governments in their strategies. Pharma can hone engagement strategies to ensure they have the right thought leaders for their scientific advisory boards and other consulting needs. Governments can view the impact of their funding by seeing new collaborations develop, bridging gaps and improving outcomes."

Lnx Pharma has analyzed over 50 disease states in just three years in business, working with major pharmaceutical companies who utilize the firm's capabilities in isolating undiscovered key opinion leaders as well as evaluating the strength of existing KOLs who have been engaged in thought leadership activities. The objective nature of the analysis helps maintain strict adherence to compliance and Sunshine Act laws applied to the pharmaceutical industry.

About Lnx Pharma
Lnx Pharma is a division of Lnx Research, LLC a privately held company based in Orange, California, dedicated to leadership in the analysis of knowledge-creating communities. Lnx Research utilizes proprietary social network analysis methods and technologies to identify and understand "The Invisible College" of key opinion leaders in order to answer questions about knowledge communities for government and commercial clients in multiple industries. For white papers on this topic, or more specific information on Lnx Pharma, go to http://www.lnxpharma.com.

Keyword Tags:
breast cancer awareness month, breast cancer, breast neoplasms, medical research, key opinion leader management, influence mapping, pharmaceutical marketing research, alliance influence map, influence mapping project, kol influence mapping, pharmaceutical research, social network analysis, sna, kol, kol management, key opinion leaders

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Bally Daily
Visit website